NCT00740922View on ClinicalTrials.gov

Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers

CompletedOBSERVATIONAL
Enrollment

563

Participants

Timeline

Start Date

July 31, 1999

Study Completion Date

April 30, 2001

Conditions
Platelet-Derived Growth FactorDiabetic FootNeoplasms
Interventions
DRUG

Sterile becaplermin gel vs. sterile placebo gel treatment 1

Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00740922 - Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers | Biotech Hunter | Biotech Hunter